 Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| OF THE INVENTION In one embodiment, the viral infection is chosen from Flaviviridea viral ... |
|
| Monocyclic L-nucleosides, analogs and uses thereof |
| Where the following terms are used in this specification, they are used as defined below. The term ... |
|
| Storage medium storing catalog information and corresponding audio data |
| It is an object of the present invention to provide a storage medium for storing catalog ... |
|
| Nucleoside compounds and uses thereof |
| The present invention is directed to nucleoside analogs and related compounds, including their ... |
|
| Composition and method for inhibiting platelet aggregation |
| OF THE INVENTION This invention is provides a method of preventing or treating diseases or ... |
|
| Non-infectious HIV particles and uses therefor |
| The present invention relates to HIV mutant constructs comprising a mutant HIV genome which has an ... |
|
| Live genetically attenuated malaria vaccine |
| Here we show by reverse genetics that selected individual genes, exemplified by UIS3 (up-regulated ... |
|
| Propargylethoxyamino nucleotides |
| OF THE PREFERRED EMBODIMENTS Reference will now be made in detail to the preferred embodiments of ... |
|
| Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases |
| The invention claimed is: 1. An aerosolized colloidal suspension that is active for the treatment ... |
|
|
Neural thread protein gene expression and detection of alzheimer's disease
| Details |
Inventors: de la Monte, Suzanne; Wands, Jack R.;
Assignee: The General Hospital Coporation (Boston, MA)
Primary Examiner: Wax; Robert A.
Assistant Examiner: Longton; Enrique D.
Attorney, Agent or Firm: Sterne,Kessler,Goldstein & Fox P.L.L.C.
The present invention is directed to recombinant hosts expressing novel proteins associated with Alzheimer's Disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. This invention is specifically directed to the recombinant hosts and vectors which contain the genes coding for the neuronal thread proteins. This invention is also directed to substantially pure neural thread protein, immunodiagnostic and molecular diagnostic methods to detect the presence of neural thread proteins, and the use of nucleic acid sequences which code for neural thread proteins in gene therapy. |
|
DETAILED DESCRIPTION A need exists for a definitive diagnostic test which can be performed on individuals suspected of having, or being at risk for AD.
The present invention satisfies such needs and provides further advantages.
The manner in which these and other objects are realized by the present invention will be apparent from the summary and detailed description set forth below.
Unless defined otherwise, various terms used herein have the same meaning as is well understood in the art to which the invention belongs.
All cited publications are incorporated herein by reference.
This invention is directed to recombinant hosts expressing novel proteins associated with Alzheimer's Disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas.
This invention is specifically directed to the recombinant hosts and vectors which contain the genes coding for the neuronal thread proteins (NTP) having molecular weights of about 8 kDa, 14 kDa, 17 kDa, 21 kDa, 26 kDa or 42 kDa.
This invention is also directed to the substantially pure neural thread proteins, immunodiagnostic and molecular diagnostic methods to detect the presence of neural thread proteins, and the use of nucleic acid sequences which code for neural thread proteins in gene therapy.
In particular, the invention includes a method for detecting and quantitating an NTP in a human subject, comprising: (a) contacting a biological sample from a human subject that is suspected of containing detectable levels of an NTP with a molecule capable of binding to the NTP; and (b) detecting the molecule bound to the NTP.
The invention additionally includes the method as above, wherein the binding molecule is selected from the group consisting of: (a) an antibody substantially free of natural impurities; (b) a monoclonal antibody; and (c) a fragment of (a) or (b).
The invention additionally includes the method as above, wherein the detecting molecule is detectably labeled and where a combination of such binding molecules is used.
The invention additionally includes a method for detecting the presence of a genetic sequence coding for an NTP in a biological sample using a polynucleotide probe derived from a recombinant human NTP of this invention
|
| Related patents |
|
|
Method of detecting neurological disease or dysfunction
What is claimed is: 1. A method for detecting the presence of nPTP in a human subject, said method comprising: (a) contacting cerebrospinal fluid or brain tissue removed ...
|
|
|
Metabolic pathway assay
This invention relates to an in vitro screening assay which identifies enzyme inhibitors. This invention allows for the simultaneous assay of many enzymes. The goal is ...
|
|
|
MurC
What is claimed is: 1. An isolated polynucleotide segment comprising a first polynucleotide sequence or the full complement of the entire length of the first ...
|
|
|
Murf gene and enzyme of Pseudomonas aeruginosa
Polynucleotides and polypeptides of Pseudomonas aeruginosa MurF, an enzyme involved in bacterial cell wall biosynthesis are provided. The recombinant MurF enzyme is ...
|
|
|
Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold
It is an object of the invention to provide a method of affecting nociception. It is an object of the invention to provide a catheter for treating pain. It is an object ...
|
|
|
Liposomal transfection method
The object of the present invention is thus a method for transfecting a cell with a nucleic acid which comprises contacting the cell with a liposomal transfection ...
|
|
|
Antihelminthic anthraquinones and method of use thereof
OF THE INVENTION All patents, patent applications, government publications, government regulations, and literature references cited in this specification are hereby ...
|
|
|
Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
The invention is directed to a new method of inducing viral mutagenesis which is useful in cell culture as well as in therapy. This method is significantly advantageous ...
|
|
|
2'-Fluoronucleosides
OF THE INVENTION The invention as disclosed herein is a compound, method and composition for the treatment of HIV, hepatitis (B or C), or abnormal cellular ...
|
|
|
Nucleoside compounds
Where the following terms are used in this specification, they are used as defined below. The terms "nucleoside" and "nucleoside analog compound" are interchangeable ...
|
|
|
Gene Therapy 
